Latest News

The advertising of prescription medicines is a ubiquitous feature of US media. However, the Trump administration has announced significant reforms that require the disclosure of complete safety warnings.

Chemist Warehouse has announced a new national partnership with DoorDash, giving customers across the country the ability to shop their favourite health, beauty, and personal care products from the convenience of their phone.

Australia’s cancer community will come together in Sydney this weekend for the 2025 PCPA Cancer Summit, the nation’s largest gathering of private cancer physicians, patient advocates, industry innovators, and policymakers.

General Manager Dr Nic Horridge said, “At Roche, we believe that health and sustainability are inseparable. The health of people depends on the health of the planet, and the choices we make today will shape both. This is both a profound responsibility and a core business strategy."

Artificial intelligence is edging closer to transforming the way new medicines are developed, with Australian company Pathkey.AI reporting encouraging results from its predictive platform, TrialKey.

The final episode of AstraZeneca’s TrailblAZers series features Professor John Skerritt, former Deputy Secretary of the Department of Health and Aged Care and TGA head, reflecting on lessons from the COVID-19 pandemic and the reforms needed to shape the future of healthcare delivery.

The Albanese Government’s Economic Reform Roundtable has generated a cascade of proposals from across departments and agencies about how to lift productivity and improve regulatory efficiency.

The US FDA has unveiled a significant regulatory advance with the introduction of its Rare Disease Evidence Principles, the latest example of a growing global momentum to accelerate the development and approval of therapies targeting rare diseases.

Mayne Pharma has moved to reassure staff and investors after media reports suggested its Salisbury manufacturing site in South Australia could be at risk of closure if its proposed merger with US company Cosette Pharmaceuticals goes ahead.

Alterity Therapeutics (ASX:ATH) has secured $20 million in new funding to accelerate the development of its lead drug candidate ATH434, a potential disease-modifying therapy for multiple system atrophy (MSA), a rare and devastating neurodegenerative disorder.

Regenerative medicine company Orthocell (ASX:OCC) has reported promising interim results from its ongoing Remplir Real-World Evidence study, reinforcing the performance of its collagen nerve wrap in routine clinical practice and laying the groundwork for international expansion.

Proteomics International Laboratories (ASX:PIQ) has unveiled new clinical results that could transform the early detection landscape for esophageal adenocarcinoma (EAC), a deadly cancer that has long eluded timely diagnosis.